Therapeutic Use:

Indications for SOTYLIZE:

Documented life-threatening ventricular arrhythmias. Maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter (AFIB/AFL) who are currently in sinus rhythm.

Limitations Of use:

Use in less severe arrhythmias even if symptomatic is not recommended. Avoid in asymptomatic ventricular premature contractions. Paroxysmal atrial fibrillation where AFIB/AFL is easily reversed (eg, Valsalva maneuver): not recommended.

Boxed Warning:

Life-threatening proarrhythmia. Should be hospitalized in a facility that can provide cardiac resuscitation, continuous ECG monitoring, and calculations of creatinine clearance. Do not start if baseline QTc >450msec; if QT prolongs ≥500msec, reduce dose, increase dosing interval, or discontinue.